Evaluation of early postoperative day 1 discharge after endoscopic endonasal pituitary adenoma resection.

complications discharge endoscopic pituitary adenoma pituitary surgery readmission

Journal

Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357

Informations de publication

Date de publication:
01 May 2022
Historique:
received: 11 01 2021
accepted: 17 05 2021
medline: 16 10 2021
pubmed: 16 10 2021
entrez: 15 10 2021
Statut: epublish

Résumé

While multiple studies have evaluated the length of stay after endonasal transsphenoidal surgery (ETS) for pituitary adenoma, the potential for early discharge on postoperative day 1 (POD 1) remains unclear. The authors compared patients discharged on POD 1 with patients discharged on POD > 1 to better characterize factors that facilitate early discharge after ETS. A retrospective chart review was performed for patients undergoing ETS for pituitary adenoma at a single tertiary care academic center from February 2005 to February 2020. Discharge on POD 1 was defined as a discharge within 24 hours of surgery. A total of 726 patients (mean age 55 years, 52% male) were identified, of whom 178 (24.5%) patients were discharged on POD 1. These patients were more likely to have pituitary incidentaloma (p = 0.001), require dural substitutes and DuraSeal (p = 0.0001), have fewer intraoperative CSF leaks (p = 0.02), and have lower postoperative complication rates (p = 0.006) compared with patients discharged on POD > 1. POD 1 patients also showed higher rates of macroadenomas (96.1% vs 91.4%, p = 0.03) and lower rates of functional tumors (p = 0.02). POD > 1 patients were more likely to have readmission within 30 days (p = 0.002), readmission after 30 days (p = 0.0001), nasal synechiae on follow-up (p = 0.003), diabetes insipidus (DI; 1.7% vs 9.8%, p = 0.0001), postoperative hypocortisolism (21.8% vs 12.1%, p = 0.01), and postoperative steroid usage (44.6% vs 59.7%, p = 0.003). The number of patients discharged on POD 1 significantly increased during each subsequent time epoch: 2005-2010, 2011-2015, and 2016-2020 (p = 0.0001). On multivariate analysis, DI (OR 7.02, 95% CI 2.01-24.57; p = 0.002) and intraoperative leak (OR 2.02, 95% CI 1.25-3.28; p = 0.004) were associated with increased risk for POD > 1 discharge, while operation epoch (OR 0.46, 95% CI 0.3-0.71; p = 0.0001) was associated with POD 1 discharge. This study demonstrates that discharge on POD 1 after ETS for pituitary adenomas was safe and feasible and without increased risk of 30-day readmission. On multivariate analysis, surgical epoch was associated with decreased risk of prolonged length of stay, while factors associated with increased risk of prolonged length of stay included DI and intraoperative CSF leak. These findings may help in selecting patients who are deemed reasonable for safe, early discharge after pituitary adenoma resection.

Identifiants

pubmed: 34653980
doi: 10.3171/2021.5.JNS2185
pii: 2021.5.JNS2185
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1337-1346

Auteurs

Siyuan Yu (S)

1Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia; and.

Mohammad Taghvaei (M)

1Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia; and.

Sarah Collopy (S)

1Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia; and.

Keenan Piper (K)

1Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia; and.

Michael Karsy (M)

1Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia; and.

Pascal Lavergne (P)

1Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia; and.

Blair Barton (B)

2Department of Otolaryngology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Chandala Chitguppi (C)

2Department of Otolaryngology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Glen D'Souza (G)

2Department of Otolaryngology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Marc R Rosen (MR)

2Department of Otolaryngology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Gurston G Nyquist (GG)

2Department of Otolaryngology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Mindy Rabinowitz (M)

2Department of Otolaryngology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Christopher J Farrell (CJ)

1Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia; and.

James J Evans (JJ)

1Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia; and.

Classifications MeSH